JAGX
NASDAQ · Pharmaceuticals
Jaguar Health Inc
$3.00
+0.02 (+0.67%)
Financial Highlights (FY 2026)
Revenue
1.98M
Net Income
-9,192,740
Gross Margin
67.2%
Profit Margin
-464.2%
Rev Growth
-1.3%
D/E Ratio
3.64
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 67.2% | 67.2% | 61.3% | 61.3% |
| Operating Margin | -414.4% | -373.0% | 27.6% | 29.3% |
| Profit Margin | -464.2% | -441.0% | 23.6% | 22.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.98M | 2.01M | 728.2K | 878.3K |
| Gross Profit | 1.33M | 1.35M | 446.4K | 538.4K |
| Operating Income | -8,207,614 | -7,481,114 | 200.8K | 257.3K |
| Net Income | -9,192,740 | -8,379,041 | 171.9K | 200.8K |
| Gross Margin | 67.2% | 67.2% | 61.3% | 61.3% |
| Operating Margin | -414.4% | -373.0% | 27.6% | 29.3% |
| Profit Margin | -464.2% | -441.0% | 23.6% | 22.9% |
| Rev Growth | -1.3% | -1.3% | -5.9% | +16.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 472.1K | 472.1K | 719.4K | 546.9K |
| Total Equity | 129.8K | 129.8K | 1.37M | 1.50M |
| D/E Ratio | 3.64 | 3.64 | 0.52 | 0.37 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -7,870,973 | -7,572,842 | 249.9K | 289.1K |
| Free Cash Flow | — | — | 132.1K | 184.4K |